Optimizing clinical trial design for assessing the efficacy of functional foods

Nutrition Reviews

Volumn 68, Issue 8, 2010, Pages 485-499

  AbuMweis, Suhad S ^a   Jew, Stephanie ^b   Jones, Peter J H ^c  

^a HASHEMITE UNIVERSITY   (Jordan)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Chronic diseases; Clinical trial; Functional foods

Indexed keywords

BIOLOGICAL MARKER;

CARDIOVASCULAR DISEASE; CIRCADIAN RHYTHM; CLINICAL PRACTICE; CLINICAL RESEARCH; COST EFFECTIVENESS ANALYSIS; CROSSOVER PROCEDURE; DIABETES MELLITUS; DIETARY INTAKE; DISEASE MARKER; EXPERIMENTAL DESIGN; FOOD SAFETY; FUNCTIONAL FOOD; HUMAN; MEDICAL ETHICS; NEOPLASM; NUTRITION; OSTEOPOROSIS; OUTCOME ASSESSMENT; PARALLEL DESIGN; PATIENT COMPLIANCE; PATIENT SELECTION; PRACTICE GUIDELINE; REVIEW; RISK ASSESSMENT; SAMPLE SIZE; STUDY DESIGN; VALIDITY; WELLBEING; COST BENEFIT ANALYSIS; ECONOMICS; EVIDENCE BASED MEDICINE; METHODOLOGY; PHYSIOLOGY; STANDARDS; TREATMENT OUTCOME;

COST-BENEFIT ANALYSIS; EVIDENCE-BASED MEDICINE; FUNCTIONAL FOOD; HUMANS; NUTRITIONAL PHYSIOLOGICAL PHENOMENA; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 77956628952     PISSN: 00296643     EISSN: 17534887     Source Type: Journal    
DOI: 10.1111/j.1753-4887.2010.00308.x     Document Type: Review

References (79)

1. Jekel JF, Katz DL, Elmore JG. Epidemiology, Biostatistics, and Preventive Medicine, 2nd edn. Philadephia: W.B. Saunders Company; 2001.
2. Yamamoto ME. Analytic nutrition epidemiology. In: Monsen ER, ed. Research: Successful Approaches, 2nd edn. Chicago: American Dietetic Association; 2003:71-86.
3. U.S. Food and Drug Administration. Claims That Can Be Made for Conventional Foods and Dietary Supplements. 2003; Available at: Http://www.fda.gov/Food/Labeling Nutrition/LabelClaims/ucm111447.htm. Accessed 7 March 2010.
4. Margetts BM, Rouse IL. Experimental studies. In: Margetts BM, Nelson M, eds. Design Concepts in Nutritional Epidemiology. New York: Oxford University Press; 1991:385-408.
5. Griel AE, Psota TL, Kris-Etheron PM. Designing, managing and conducting a clincal nutrition study. In: Monsen ER, Van Horn L, eds. Research: Successful Approaches. Chicago: American Dietetic Association; 2008:101-116.
6. Derr JA. Statistical aspects of controlled diet studies. In: Dennis BH, ErshowAG, Obarzanek E, Clevidence BA, eds.Well- Controlled Diet Studies in Humans, A Practical Guide to Design and Management, 3rd edn. Chicago: American Dietetic Association; 1999:10-18.
7. Sibbald B, Roberts C. Understanding controlled trials: Crossover trials. BMJ. 1998;316:1719-1720.
8. Garcia R, Benet M, Arnau C, Cobo E. Efficiency of the crossover design: An empirical estimation. Stat Med. 2004;23: 3773-3780.
9. Sandstrom B. Quality criteria in human experimental nutrition research. Eur J Clin Nutr. 1995;49:315-322.
10. Clevidence BA, Fong AKH, Todd K, et al. Planning diet studies. In: Dennis BH, Ershow AG, Obarzanek E, Clevidence BA, eds. Well-Controlled Diet Studies in Human, A Practical Guide to Design and Management, 3rd edn. Chicago: American Dietetic Association; 1999:142-154.
11. Splett PL. Outcomes research and economic analysis. In: Monsen ER, ed. Research: Successful Approaches, 2nd edn. Chicago: American Dietetic Association; 2003:291-312.
12. Hulley SB, Newman TB, Cummings SR. Choosing the study subjects: Specification, sampling and recruitment. In: Hulley SB, Cummings SR, Browner WS, Grady DG, Newman TB, eds. Designing Clinical Research: An Epidemiologic Approach, 3rd edn. Philadelphia: Lippincott Williams and Wilkins; 2007:27-36.
13. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Food Safety and Applied Nutrition. Guidance for Industry: Evidence-Based Review System for the Scientific Evaluation of Health Claims. 2009; Available at: Http://www.fda.gov/Food/GuidanceCompliance RegulatoryInformation/GuidanceDocuments/FoodLabeling Nutrition/ucm073332.htm. Accessed 28 November 2009.
14. Health Canada, Health Protection Branch, Food Directorate. Guidelines Concerning the Safety and Physiological Effects of Novel Fibre Sources and Food Products Containing Them. 1997; Available at: Http://www.hc-sc.gc.ca/fn-an/ legislation/guide-ld/novel-fibre-nouvelle-tc-tm-eng.php. Accessed 28 November 2009.
15. Plourde M, Jew S, Cunnane SC, Jones PJH. Conjugated linoleic acids: Why the discrepancy between animal and human studies? Nutr Rev. 2008;66:415-421.
16. Jones PJH, Howell T, MacDougall DE, Feng JY, Parsons W. Short-term administration of tall oil phytosterols improves plasma lipid profiles in subjects with different cholesterol levels. Metab-Clin Exp. 1998;47:751-756.
17. Miettinen TA, Puska P, Gylling H, Vanhanen H, Vartiainen E. Reduction of serum-cholesterol with sitostanol-ester margarine in a mildly hypercholesterolemic population. N Engl J Med. 1995;333:1308-1312.
18. Berger A, Jones PJ, AbuMweis SS. Plant sterols: Factors affecting their efficacy and safety as functional food ingredients. Lipids Health Dis. 2004;3:5.
19. Cummings SR, Grady D, Hulley SB. Designing a randomized blinded trial. In: Hulley SB, Cummings SR, Browner WS, Grady DG, Newman TB, eds. Designing Clinical Research: An Epidemiologic Approach, 3rd edn. Philadelphia: Lippincott Williams and Wilkins; 2007:147-162.
20. Hallikainen MA, Sarkkinen ES, Uusitupa MIJ. Plant stanol esters affect serum cholesterol concentrations of hypercholesterolemic men and women in a dose-dependent manner. J Nutr. 2000;130:767-776.
21. Hendriks HFJ, Weststrate JA, van Vliet T, Meijer GW. Spreads enriched with three different levels of vegetable oil sterols and the degree of cholesterol lowering in normocholesterolaemic and mildly hypercholesterolaemic subjects. Eur J Clin Nutr. 1999;53:319-327.
22. Katan MB, Grundy SM, Jones P, LawM,Miettinen T, Paoletti R. Efficacy and safety of plant stanols and sterols in the management of blood cholesterol levels. Mayo Clin Proc 2003;78:965-978.
23. Ooi EM, Watts GF, Barrett PH, et al. Dietary plant sterols supplementation does not alter lipoprotein kinetics in men with the metabolic syndrome. Asia Pac J Clin Nutr. 2007;16: 624-631.
24. Klerman EB. Clinical aspects of human circadian rhythms. J Biol Rhythms. 2005;20:375-386.
25. Young ME. The circadian clock within the heart: Potential influence on myocardial gene expression, metabolism, and function. Am J Physiol Heart Circ Physiol. 2006;290:H1- 16.
26. AbuMweis SS, Vanstone CA, Lichtenstein AH, Jones PJH. Plant sterol consumption frequency affects plasma lipid levels and cholesterol kinetics in humans. Eur J Clin Nutr. 2008;63:747-755.
27. van het Hof KH, West CE, Weststrate JA, Hautvast JGAJ. Dietary factors that affect the bioavailability of carotenoids. J Nutr. 2000;130:503-506.
28. Jones PJH, Vanstone CA, Raeini-Sarjaz M, St-Onge MP. Phytosterols in low- and nonfat beverages as part of a controlled diet fail to lower plasma lipid levels. J Lipid Res. 2003;44: 1713-1719.
29. Devaraj S, Jialal I, Vega-Lopez S. Plant sterol-fortified orange juice effectively lowers cholesterol levels in mildly hypercholesterolemic healthy individuals. Arterioscler Thromb Vasc Biol. 2004;24:E25-E28.
30. Romer S, Garti N. The activity and absorption relationship of cholesterol and phytosterols. Colloid Surf A-Physicochem Eng Asp. 2006;282:435-456.
31. Naidu KA. Vitamin C in human health and disease is still a mystery? An overview. Nutr J. 2003;2:7.
32. Shimoni E. Stability and shelf life of bioactive compounds during food processing and storage: Soy isoflavones. J Food Sci. 2004;69:R160-R166.
33. Kris-Etherton PM, Dietschy J. Design criteria for studies examining individual fatty acid effects on cardiovascular disease risk factors: Human and animal studies. Am J Clin Nutr. 1997;65(Suppl):S1590-S1596.
34. Kay CD, Kris-Etheron PM, Psota TL, Maddox Bagshaw D, West SG. Clinical nutrition studies: Maximizing opportunities and managing the challenges. In: Berdanier CD, Dwyer J, Feldman EF, eds. Handbook of Nutrition and Food, 2nd edn. Boca Raton, FL: CRC Press; 2008:693-714.
35. Jacobsen C. Omega-3s in food emulsions: Overview and case studies. AgroFOOD industry hi-tech. 2008;19:9-12.
36. Moghadasian MH. Advance in dietary enrichment with n-3 fatty acids. Crit Rev Food Sci Nutr. 2008;48:402-410.
37. Borneo R, Kocer D, Ghai G, Tepper BJ, KarweMV. Stability and consumer acceptance of long-chain omega-3 fatty acids (eicosapentaenoic acid, 20:5, n-3 and docosahexaenoic acid, 22:6, n-3) in cream-filled sandwich cookies. J Food Sci. 2007;72(Suppl):S049-S054.
38. Nielsen NS, Debnath D, Jacobsen C. Oxidative stability of fish oil enriched drinking yoghurt. Int Dairy J. 2007;17:1478-1485.
39. Martini S, Thurgood JE, Brothersen C, Ward R, McMahon DJ. Fortification of reduced-fat cheddar cheese with n-3 fatty acids: Effect on off-flavor generation. J Dairy Sci. 2009;92: 1876-1884.
40. Drewnowski A, Gomez-Carneros C. Bitter taste, phytonutrients, and the consumer: A review. Am J Clin Nutr. 2000;72: 1424-1435.
41. Klein BP, Perry AK, Adair N. Incorporating soy proteins into baked products for use in clinical studies. J Nutr. 1995;125(Suppl):S666-S674.
42. Aldin E, Reimeier CA, Murphy P. Bitterness of soy extracts containing isoflavones and saponins. J Food Sci. 2006;71: S211-S215.
43. Yeu K, Lee Y, S.Y. L. Consumer acceptance of an extruded soy-based high-protein breakfast cereal. J Food Sci. 2008;73:S20-S25.
44. Lang JM. The use of a run-in to enhance compliance. Stat Med. 1990;9:87-93.
45. Keech AC, Gebski V. Managing the resource demands of a large sample size in clinical trials: Can you succeed with fewer subjects? Med J Aust. 2002;177:445-447.
46. Pablos-Mendez A, Barr G, Shea S. Run-in periods in randomized trials: Implications for the application of results in clinical practice. JAMA. 1998;279:222-225.
47. Aitken L, Gallagher R, Madronio C. Principles of recruitment and retention in clinical trials. Int J Nurs Pract. 2003;9:338-346.
48. Thompson FE, Subar AF. Dietary assessment methodology. In: Coulston AC, Boushey CJ, eds. Nutrition in the Prevention and Treatment of Disease, 2nd edn. Burlington, MA, San Diego, CA, London: Elsevier Inc; 2008:3-39.
49. Lichtenstein AH, Prewitt TE, Rasmussen H, Heiser CR. Managing participants and maximizing compliance. In: Dennis BH, Ershow AG, Obarzanek E, Clevidence BA, eds. Well-Controlled Diet Studies in Humans, A Practical Guide to Design and Management, 3rd edn. Chicago: American Dietetic Association; 1999:96-108.
50. Smiciklas-Wright H, Mitchell DC, Ledikwe JH. Dietary intake assessment: Methods for adults. In: Berdanier CD, Dwyer J, Feldman EB, eds. Handbook of Nutrition and Food, 2nd edn. Boca Raton, FL: CRC Press; 2008:493-507.
51. Dwyer J. Overview of nutritional epidemiology. In: Shils ME, Olson JA, ShikeM, eds. Dietary Assessment in Modern Nutrition in Health and Disease, 9th edn. Baltimore: LippincottWilliams and Wilkins; 1999:937-959.
52. Swain JF. Biological sample collection and biological markers of dietary compliance. In: Dennis BH, Ershow AG, Obarzanek E, Clevidence BA, eds. Well-Controlled Diet Studies in Humans, A Practical Guide to Design and Management. Chicago: American Dietetic Association; 1999:379-389.
53. Lampe JW, Rock CL. Biomarkers and their use in nutrition intervention. In: Coulston AC, Boushey CJ, eds. Nutrition in the Prevention and Treatment of Disease, 2nd edn. BurlingtonMA, San Diego CA, London: Elsevier Inc; 2008:3-39.
54. Arab L. Biomarkers of fat and fatty acid intake. J Nutr. 2003;133(Suppl):S925-S932.
55. Bingham SA. Biomarkers in nutritional epidemiology. Public Health Nutr. 2002;5:821-827.
56. Hunter D. Biochemical indicators of dietary intake. In: Willet W, ed. Nutritional Epidemiology, 2nd edn. New York: Oxford University Press; 1998:174-243.
57. Spencer JPE, Abd El Mohsen MM, Minihane AM, Mathers JC. Biomarkers of the intake of dietary polyphenols: Strengths, limitations and application in nutrition research. Br J Nutr. 2008;99:12-22.
58. Manolio T. Novel risk markers and clinical practice. N Engl J Med. 2003;349:1587-1589.
59. De Gruttola VG, Clax P, DeMets DL, et al. Considerations in the evaluation of surrogate endpoints in clinical trials: Summary of a National Institutes of Health workshop. Control Clin Trials. 2001;22:485-502.
60. Herson J. The use of surrogate endpoints in clinical trials (an introduction to a series of four papers). Stat Med. 1989;8: 403-404.
61. Wittes J, Lakatos E, Probstfield J. Surrogate endpoints in clinical trials: Cardiovascular diseases. Stat Med. 1989;8:415-425.
62. Lonn E. The use of surrogate endpoints in clinical trials: Focus on clinical trials in cardiovascular diseases. Pharmacoepidemiol Drug Saf. 2001;10:497-508.
63. Prentice RL. Surrogate endpoints in clinical trials: Definition and operational criteria. Stat Med. 1989;8:431-440.
64. Wang Y, Jones PJH. Dietary conjugated linoleic acid and body composition. Am J Clin Nutr. 2004;79(Suppl):S1153-S1158.
65. Lassere MN. The Biomarker-Surrogacy Evaluation Schema: A review of the biomarker-surrogate literature and a proposal for a criterion-based, quantitative, multidimensional hierarchical levels of evidence schema for evaluating the status of biomarkers as surrogate endpoints. Stat Methods Med Res. 2008;17:303-340.
66. Rasnake CM, Trumbo PR, Heinonen TM. Surrogate endpoints and emerging surrogate endpoints for risk reduction of cardiovascular disease. Nutr Rev. 2008;66:76-81.
67. Revkin JH, Shear CL, Pouleur HG, Ryder SW, Orloff DG. Biomarkers in the prevention and treatment of atherosclerosis: Need, validation, and future. Pharmacol Rev. 2007;59:40-53.
68. Johnson JR, Williams G, Pazdur R. End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol. 2003;21:1404-1411.
69. Kelloff GJ, Bast RC, Jr, Coffey DS, et al. Biomarkers, surrogate endpoints, and the acceleration of drug development for cancer prevention and treatment: An update prologue. Clin Cancer Res. 2004;10:3881-3884.
70. European Medicines Agency, Committee for Medicinal Products for Human Use. Guideline on the Evaluation of New Medicinal Products in the Treatment of Primary Osteoporosis. Doc. Ref. CPMP/EWP/552/95 Rev. 2. 2005; http://www.emea. europa.eu/pdfs/human/ewp/55295enfin.pdf. Accessed October 2009.
71. Health Canada, Food Directorate, Health Products and Food Branch, Bureau of Nutritional Sciences. Guidance Document for Preparing a Submission for Food Health Claims. March 2009; Available at: Http://www.hc-sc.gc.ca/fn-an/ legislation/ guide-ld/health-claims-guidance-orientation-allegationssante- eng.php. Accessed 28 November 2009.
72. European Food Safety Authority. Scientific and Technical Guidance for the Preparation and Presentation of the Application for Authorisation of a Health Claim. 2007; Available at: Http://www.efsa.europa.eu/en/scdocs/scdoc/ 530.htm. Accessed 28 November 2009.
73. Institutes of Food Technologists Expert Report. Functional Foods: Opportunities and Challenges. http://www.ift.org/ Knowledge-Center/Read-IFT- Publications/Science-Reports/ Expert-Reports/Functional-Foods.aspx. Accessed 12 March 2010.
74. Swinscow TDV. Statistics at Square One. Revised by MJ Campbell, University of Southampton: BMJ Publishing Group; 1997; Available at: Http://www.bmj.com/statsbk/. Accessed October 2009.
75. Browner WS, Newman TB, Hulley SB. Estimating sample size and power: Applications and examples. In: Hulley SB, Cummings SR, Browner WS, Grady DG, Newman TB, eds. Designing Clinical Research: An Epidemiologic Approach, 3rd edn. Philadelphia: Lippincott Williams and Wilkins; 2007:65-96.
76. Littell RC, Stroup WW, Freund RJ. SAS for Linear Models, 4th edn. Cary, NC: SAS Institute; 2002.
77. International Conference on Harmanization Harmonised Tripartite Guidelines. Guidelines for Good Clinical Practice. 1996; Available at: Http://www.ich.org/cache/compo/276- 254-1.html. Accessed 28 November 2009.
78. U.S. Food and Drug Administration. Clinical Trials Guidance Documents US Food and Drug Administration. 2009; Available at: Http://www.fda.gov/ RegulatoryInformation/ Guidances/ucm122046.htm. Accessed 28 November 2009.
79. Health Canada. Guidance Documents for Clinical Trials. 2009; Available at: Http://www.hc-sc.gc.ca/dhp-mps/ prodpharma/applic-demande/guide-ld/clini/ index-eng.php. Accessed 28 November 2009.